Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease

BackgroundCachexia is associated with poor prognosis in chronic liver disease (CLD), yet robust predictors remain poorly defined. This study examined clinical factors and serum biomarkers associated with cachexia in patients with CLD.MethodsWe analyzed 356 of 526 patients with CLD who had complete c...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Takatsugu Tanaka, Goki Suda, Masatsugu Ohara, Osamu Maehara, Tomoka Yoda, Qingjie Fu, Zijian Yang, Naohiro Yasuura, Akimitsu Meno, Takashi Sasaki, Risako Kohya, Takashi Kitagataya, Naoki Kawagishi, Masato Nakai, Takuya Sho, Shunsuke Ohnishi, Naoya Sakamoto
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2026-02-01
Σειρά:	Frontiers in Nutrition
Θέματα:	biomarker cachexia chronic liver disease fibroblast growth factor liver cirrhosis
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fnut.2026.1730695/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!